The useful question is not “Can an AI talk about chemistry?” It is “Can this team finish a recurring data task with less effort, without losing traceability or control?” That is a workflow problem before it is a model-selection problem.
Prepare
Align approved files, identifiers, units and time points before interpretation.
Preserve
Keep every result tied to its source, method, transformation and exception.
Decide
Return scientific interpretation and formal approval to the responsible team.
Three roles, three preparation bottlenecks
Formulation: compare experiments.
Keep the context. Align experiment sheets and result exports, then place formulation parameters beside response curves. The scientist decides comparability, meaning and the next experiment.
Analytical & QC: assemble trends.
Keep results tied to lot, time point, method and source. Missing pulls remain explicit; preparation does not make shelf-life, OOS or release decisions.
Scientific data: reproduce transformations.
Reconcile schemas and units, preserve row counts and document every mapping. Ambiguous fields become visible exceptions rather than silent guesses.
Use models for organization.
Extraction, mapping proposals, source retrieval and narrative drafts can benefit from model assistance.
Use approved methods for numbers.
Calculations and charts should come from inspectable procedures; reviewers approve ambiguous mappings and interpretation.
Control the whole data path
The standard Matrix setup is offline and on-site. Working records, questions, outputs and logs stay in the customer’s local environment, and Synexas staff do not view or receive them. The one exception is a proof on your task if you ask for one: data you authorize, under an NDA, deleted afterwards. Local access, retention and quality-system responsibilities still belong to the customer.
Measure the first workflow, including review
Return preparation time to scientific work. Compare the same workflow before and after assistance, including setup, corrections and review. Preserve source fidelity, missing observations and unresolved mappings. The useful outcome is more capacity for analysis and decisions, not faster unchecked output.
This note synthesizes public guidance and scientific-data research. Customer-specific usefulness and controls require a scoped workflow evaluation.
Sources and further reading
- FDA / ICH Q8(R2): Pharmaceutical Development
Formulation attributes, excipients, process understanding and experimental design.
- FDA / ICH Q14: Analytical Procedure Development
Science- and risk-based analytical procedure development.
- FDA / ICH Q2(R2): Validation of Analytical Procedures
Validation context for analytical procedures and their intended use.
- FDA / ICH Q1E: Evaluation of Stability Data
Scientific evaluation of stability observations over time.
- FDA: Data Integrity and Compliance With Drug CGMP
Reliable, accurate data and risk-based data-integrity controls.
- Wilkinson et al.: The FAIR Guiding Principles (2016)
Primary research on metadata, interoperability, provenance and reusable scientific workflows.